CN115768431A - 治疗类风湿性关节炎中的rabeximod - Google Patents

治疗类风湿性关节炎中的rabeximod Download PDF

Info

Publication number
CN115768431A
CN115768431A CN202180042179.5A CN202180042179A CN115768431A CN 115768431 A CN115768431 A CN 115768431A CN 202180042179 A CN202180042179 A CN 202180042179A CN 115768431 A CN115768431 A CN 115768431A
Authority
CN
China
Prior art keywords
rabeximod
composition
use according
rheumatoid arthritis
weeks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180042179.5A
Other languages
English (en)
Chinese (zh)
Inventor
U·布乔科伦德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN115768431A publication Critical patent/CN115768431A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Indole Compounds (AREA)
  • Cosmetics (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
CN202180042179.5A 2020-06-10 2021-06-10 治疗类风湿性关节炎中的rabeximod Pending CN115768431A (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP20179279.3 2020-06-10
EP20179279 2020-06-10
EP20179277.7 2020-06-10
EP20179239 2020-06-10
EP20179277 2020-06-10
EP20179239.7 2020-06-10
EP20180706 2020-06-18
EP20180706.2 2020-06-18
PCT/EP2021/065697 WO2021250199A1 (en) 2020-06-10 2021-06-10 Rabeximod in the treatment of rheumatoid arthritis

Publications (1)

Publication Number Publication Date
CN115768431A true CN115768431A (zh) 2023-03-07

Family

ID=76305939

Family Applications (4)

Application Number Title Priority Date Filing Date
CN202180042179.5A Pending CN115768431A (zh) 2020-06-10 2021-06-10 治疗类风湿性关节炎中的rabeximod
CN202510521204.8A Pending CN120383602A (zh) 2020-06-10 2021-06-10 用于制备结晶形式的rabeximod的方法
CN202180042114.0A Pending CN115697308A (zh) 2020-06-10 2021-06-10 包含结晶形式的rabeximod的口服制剂
CN202180041778.5A Pending CN115698010A (zh) 2020-06-10 2021-06-10 用于制备结晶形式的rabeximod的方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN202510521204.8A Pending CN120383602A (zh) 2020-06-10 2021-06-10 用于制备结晶形式的rabeximod的方法
CN202180042114.0A Pending CN115697308A (zh) 2020-06-10 2021-06-10 包含结晶形式的rabeximod的口服制剂
CN202180041778.5A Pending CN115698010A (zh) 2020-06-10 2021-06-10 用于制备结晶形式的rabeximod的方法

Country Status (8)

Country Link
US (3) US12594274B2 (https=)
EP (3) EP4164650A1 (https=)
JP (3) JP2023529001A (https=)
KR (3) KR20230022880A (https=)
CN (4) CN115768431A (https=)
AU (3) AU2021290174A1 (https=)
CA (3) CA3181629A1 (https=)
WO (3) WO2021250197A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230022880A (ko) 2020-06-10 2023-02-16 사익손 아베 라벡시모드의 결정성 형태를 포함하는 경구 제형
US11643415B1 (en) 2021-12-09 2023-05-09 Cyxone Ab Rabeximod compounds

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050288296A1 (en) * 2004-06-17 2005-12-29 Jan Bergman Alkyl substituted indoloquinoxalines
CN112513044A (zh) * 2018-07-13 2021-03-16 吉利德科学公司 吡咯并[1,2-b]哒嗪衍生物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8600260D0 (sv) 1986-01-21 1986-01-21 Lundblad Leif Substituerade indolokinoxaliner
SE504289C2 (sv) * 1994-06-23 1996-12-23 Leif J I Lundblad Användning av vissa indolo-2,3b-kinoxaliner för framställning av ett läkemedel för inhibering av enzymet HIV-integras
JPH08165278A (ja) 1994-12-14 1996-06-25 Kawaken Fine Chem Co Ltd １−置換トリプタミン化合物の製造方法
SE504862C2 (sv) 1994-12-27 1997-05-20 Leif J I Lundblad Användning av vissa indolo-§2,3b¤-kinoxaliner för framställning av ett läkemedel för skydd av DNA i initieringsfasen och/eller promotionsfasen av karcinogenes och för förhindrande av oxidativ stress i patienter med sjukdomar relaterade till fria radikaler
DE19516804A1 (de) * 1995-05-08 1996-11-14 Hoechst Ag Isoindolinpigmente auf Basis von Aminochinoxalindionen
US6333327B2 (en) 2000-02-18 2001-12-25 Leif J. I. Lundblad Method for the treatment of Multiple Sclerosis
SE516067C2 (sv) 2000-02-18 2001-11-12 Lundblad Leif J I Användning av en förening för framställning av ett läkemedel
TW200410921A (en) * 2002-11-25 2004-07-01 Hoffmann La Roche Mandelic acid derivatives
ATE382623T1 (de) * 2004-06-09 2008-01-15 Hoffmann La Roche Octahydropyrrolo(3,4-c)pyrrolderivate und deren verwendung als antivirale mitteln
WO2008066151A1 (fr) * 2006-11-30 2008-06-05 Tokyo Institute Of Technology Nouveau dérivé curcumine
CN102115457B (zh) 2011-03-05 2012-11-21 太原理工大学 一种n-乙基咔唑的制备方法
US20150079111A1 (en) * 2012-06-05 2015-03-19 Jonas Axelsson Mechanism, diagnostic, and treatments for complications of renal failure
EA201500942A1 (ru) 2013-03-15 2016-03-31 Виронова Херпес Аб ПРОТИВОВИРУСНЫЙ ИНДОЛО[2,3-b]ХИНОКСАЛИН
AU2016272089B2 (en) 2015-06-03 2021-02-18 Triastek, Inc. Dosage forms and use thereof
CN105061432B (zh) * 2015-07-16 2017-09-29 河北大学 6H‑吲哚[2,3‑b]喹喔啉衍生物、药物组合物及其制备和应用
KR20230022880A (ko) 2020-06-10 2023-02-16 사익손 아베 라벡시모드의 결정성 형태를 포함하는 경구 제형
EP4164649A1 (en) 2020-06-10 2023-04-19 Cyxone AB New use of rabeximod
US11643415B1 (en) * 2021-12-09 2023-05-09 Cyxone Ab Rabeximod compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050288296A1 (en) * 2004-06-17 2005-12-29 Jan Bergman Alkyl substituted indoloquinoxalines
CN112513044A (zh) * 2018-07-13 2021-03-16 吉利德科学公司 吡咯并[1,2-b]哒嗪衍生物

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"Study to Evaluate the Efficacy and Safety of Orally Administered Rob 803 When Added to Methotrexate", pages 2, Retrieved from the Internet <URL:https://clinicaltrials.gov/study/NCT00525213?cond=Study%20 to%20Evaluate%20the%20Efficacy%20and%20Safety%20of%20Orally%20Administered%20Rob%20803%20When%20Added%20to%20Methotrexate%20&rank=1> *
HULTQVIST, M ET AL.: "The novel small molecule drug Rabeximod is effective in reducing disease severity of mouse models of autoimmune disorders", 《ANNALS OF THE RHEUMATIC DISEASES 》, vol. 68, no. 1, 31 January 2009 (2009-01-31), pages 130 - 135, XP009524176, DOI: 10.1136/ard.2007.085241 *
刘喜德，万力生主编: "《类风湿关节炎的诊断与治疗》", 30 November 2005, 北京：人民军医出版社, pages: 196 *

Also Published As

Publication number Publication date
CA3181637A1 (en) 2021-12-16
KR20230022882A (ko) 2023-02-16
US12594274B2 (en) 2026-04-07
JP2023529877A (ja) 2023-07-12
WO2021250199A1 (en) 2021-12-16
CA3181646A1 (en) 2021-12-16
WO2021250204A1 (en) 2021-12-16
JP2023533662A (ja) 2023-08-04
AU2021289006A1 (en) 2023-02-09
EP4165043A1 (en) 2023-04-19
EP4164616A1 (en) 2023-04-19
CN115698010A (zh) 2023-02-03
US20220133717A1 (en) 2022-05-05
WO2021250197A1 (en) 2021-12-16
US20230227455A1 (en) 2023-07-20
EP4164650A1 (en) 2023-04-19
CA3181629A1 (en) 2021-12-16
AU2021290174A1 (en) 2023-02-09
JP2023529001A (ja) 2023-07-06
KR20230022880A (ko) 2023-02-16
US20230227456A1 (en) 2023-07-20
CN115697308A (zh) 2023-02-03
CN120383602A (zh) 2025-07-29
AU2021290173A1 (en) 2023-02-09
KR20230022881A (ko) 2023-02-16

Similar Documents

Publication Publication Date Title
JP2016534074A5 (https=)
KR20110133602A (ko) 옥시코돈 및 날록손을 포함하는 즉시 방출 제약 조성물
US11793776B1 (en) Methods of administering solriamfetol to lactating women
JP2016534074A (ja) 血球減少を予防又は治療するための薬物の製造におけるイカリチンの使用
JP6966840B2 (ja) 神経変性疾患の改善用医薬
JP2023516951A (ja) アルペリシブおよび６－（２，４－ジクロロフェニル）－５－［４－［（３ｓ）－１－（３－フルオロプロピル）ピロリジン－３－イル］オキシフェニル］－８，９－ジヒドロ－７ｈ－ベンゾ［７］アヌレン－２－カルボン酸を含む組合せ物
JP2001507024A (ja) 関節炎の新規処置
CA3230291A1 (en) Dosing regimens associated with extended release paliperidone injectable formulations
CN115768431A (zh) 治疗类风湿性关节炎中的rabeximod
WO2024145545A2 (en) Methods of administering solriamfetol to lactating women
JP2025081700A (ja) 改変剤形を調製する方法および関連する構成成分
US12064411B1 (en) Methods of administering solriamfetol to lactating women
KR102512518B1 (ko) 페마피브레이트를 함유하는 의약
WO2021244637A1 (en) Topical administration of 2- (diethylamino) ethyl 2- (4-isobutylphenyl) propionate for treatment of diseases
US20110281892A1 (en) Method and formulation for cold treatment in adults and children with increased safety
CN115887396B (zh) 一种醋甲唑胺口崩片及其制备方法和应用
Haigh et al. Multiple adverse effects of pyridium: a case report
WO2026032924A1 (en) Camlipixant in combination with cyp3a4 and/or cyp2c8 inducers for use in the treatment of chronic cough
BHATTACHARYA et al. The Great Masquerade: A Rare Presentation of Spinal Tuberculoma.
WO2025103428A1 (zh) 中重度斑块型银屑病的治疗
Berens Plastic compressor for enucleation and evisceration
JPH0343248B2 (https=)
Jordan Principles of drug administration
Steele INTUNIV™(guanfacine) Extended-Release Tablets
Ann Riehl et al. 128. NUTRITION FOR 4 ENTITIES: HYPERTENSION, HYPERLIPIDEMIA, DIABETES & OBESITY

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination